Akero Therapeutics Investor Relations Material

Akero Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily engaged in developing innovative treatments for serious metabolic diseases with significant unmet medical needs. The company's primary focus is on its lead product candidate, efruxifermin (EFX), which is in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease characterized by fat accumulation and inflammation in the liver. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.